| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9200 | Floxuridine | Floxuridine | 500 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 1970 | Jan 1, 1984 | In Use | ||
| C9297 | Omacetaxine | Synribo | 0.01 mg | Chemotherapy | Plant Alkaloid | BCR-ABL | No | 2012 | Apr 1, 2013 | Dec 31, 2013 | No Longer Used | |
| J9262 | Omacetaxine | Synribo | 0.01 mg | Chemotherapy | Plant Alkaloid | BCR-ABL | No | 2012 | Jan 1, 2014 | In Use | ||
| S0115 | Bortezomib | Velcade | 3.5 mg | Chemotherapy | Proteasome Inhibitor | 26S | No | 2003 | Jan 1, 2004 | Dec 31, 2004 | No Longer Used | |
| Momelotinib | Ojjaara | Multiple | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2023 | In Use | ||||
| J9198 | Gemcitabine HCl | Infugem | 100mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2018 | Jul 1, 2020 | In Use | ||
| C9076 | Lisocabtagene maraleucel | Breyanzi | Immunotherapy | CAR-T | CD19 | No | 2021 | Jul 23, 2021 | Sep 27, 2021 | No Longer Used | ||
| J2930 | Methylprednisolone Sodium Succinate | A-Methapred, SOLU-medrol | 125 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | Jan 1, 1997 | Apr 17, 2024 | No Longer Used | |
| J1010 | Methylprednisolone acetate | Methylprednisolone acetate | 1mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1959 | Apr 17, 2024 | In Use | ||
| NA | Nintedanib | Ofev | 100 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR, FLT3 | Yes | 2014 | In Use | |||
| C9021 | Obinutuzumab | Gazyva | 10 mg | Immunotherapy | Monoclonal Antibody | CD20 | No | 2013 | Apr 4, 2014 | Dec 31, 2014 | No Longer Used | |
| J2783 | Rasburicase | Elitek, Fasturtec | 0.5 mg | Ancillary Therapy | Metabolic Agent | Enzyme | No | 2002 | Jan 1, 2004 | In Use | ||
| J9213 | Interferon Alfa-2a | Roeferon- A | 3 million units | Immunotherapy | Cytokine | Interferon | No | 2002 | Jan 1, 2009 | In Use | ||
| NA | Dostarlimab | Jemperli | 50mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | Yes | 2021 | In Use | |||
| Q2054 | Lisocabtagene maraleucel | Breyanzi | Immunotherapy | CAR-T | CD19 | No | 2021 | Sep 27, 2021 | In Use | |||
| C9084 | Loncastuximab tesirine | Zylonta | 0.1mg | Immunotherapy | Drug Antibody Conjugate | CD19 | No | 2021 | Sep 27, 2021 | Mar 25, 2022 | In Use | |
| Pacritinib | Vonjo | 100mg | Chemotherapy | Tyrosine Kinase Inhibitor | JAK2, FLT3 | Yes | 2022 | In Use | ||||
| NA | Ruxolitinib | Jakafi | 15 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| NA | Ruxolitinib | Jakafi | 5 mg | Chemotherapy | Enzyme Inhibitor | JAK 1/2 | Yes | 2011 | In Use | |||
| Q5117 | Trastuzumab-anns | Kanjinti | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2019 | Oct 1, 2019 | In Use | ||
| NA | Abiraterone acetate | Zytiga | 250 mg | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Yes | 2011 | In Use | |||
| J9036 | Bendamustine HCL | Belrapzo | 1mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2018 | Jul 1, 2019 | In Use | ||
| C9257 | Bevacizumab | Avastin | 0.25 mg | Immunotherapy | Monoclonal Antibody | VEGFR | No | 2004 | Jan 1, 2010 | In Use | ||
| J9074 | Cyclophosphamide (sandoz) | Cyclophosphamide (sandoz) | 5mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2014 | Apr 17, 2024 | In Use | ||
| J9203 | Gemtuzumab ozogamicin | Mylotarg | 0.1 mg | Immunotherapy | Drug Antibody Conjugate | CD33 | No | 2000 | Jan 1, 2018 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home